Gary Owens, MD, president of Gary Owens Associates, outlines the challenges of screening for pulmonary arterial hypertension (PAH).
Because pulmonary arterial hypertension (PAH) is rare, there really isn't any good screening protocol, said Gary Owens, MD, president of Gary Owens Associates. Owens presented his talk, "The Latest Evidence on Emerging Therapies and Innovations in PAH Management," at this year's National Association of Managed Care Physicians Forum, which is taking place April 21 and 22 in Orlando, Florida.
Transcript
What is the current state of PAH screening and assessment in the United States?
First of all, when we talk about PAH, we're really talking about 1 particular subgroup of a larger group called pulmonary hypertension, of which there are 5 categories. But PAH, pulmonary arterial hypertension, is classified by the World Health Organization as type 1. It's a fairly rare condition as best we know. It might be about 15 cases per 1 million, half of which are genetic and the other half of which are idiopathic.
Because it's a rare disorder, it really doesn't have a good screening protocol, nor is there anything recommended for screening in the guidelines. That being said, patients often present with very nonspecific symptoms and have quite a bit of a protracted journey from presentation of symptoms, which again are nonspecific. Shortness of breath can certainly be due to any number of diseases. That may be often followed by things like fatigue, weakness, chest pain—again, very nonspecific—although in people with PAH, that shortness of breath gets very profound, may even occur at rest. And it's at that point when lots of other conditions have been ruled out, that really the diagnostic journey begins. And that can be pretty complicated. It can take 2 to 3 years sometimes before a patient gets diagnosed.
So the bottom line, not a lot of good screening, and even when symptoms present, because they are very nonspecific, it does take a while to get to a diagnosis and even confirming that diagnosis can be a bit difficult.
In this interview with The American Journal of Managed Care®, Katie Queen, MD, addresses the complexity of obesity as a medical condition, pivoting to virtual care while ensuring that patients who lived in a rural location continued to receive adequate care, and the importance of integrating awareness of obesity and chronic disease prevention into local food culture.
Read More
Recent T1D Research Contradicts Common Assumptions About Patients
November 15th 2023Michael Fang, PhD, researcher and assistant professor in the division of Cardiovascular and Clinical Epidemiology at Johns Hopkins University, discussed recent findings in the type 1 diabetes (T1D) space that may alter the way providers address diabetes diagnoses.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment
November 9th 2023Posters presented at the 2023 Fall Clinical Dermatology Conference evaluated how label warnings may affect new treatment initiation and real-word switching patterns for patients starting risankizumab.
Read More
Innovation in Value-Based Care Requires More Data, Patient-Centered Thinking
November 9th 2023In a panel discussion at the 2023 Patient-Centered Oncology Care® meeting held in Nashville, Tennessee, experts discussed the Enhancing Oncology Model and themes in the movement toward value-based care in oncology.
Read More